Lonza adds its first sterile drug product fill-finish facility to its network after acquiring Novartis’ Swiss plant, building on its parenteral drug product development and testing capabilities for clinical trial supply.
Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.
Sterile fill-finish capabilities will be available to clinical stage customers as iBio activates its operations for biopharmaceutical products after entering a supply agreement.
The global vaccines market will develop at a rate of 6% through to 2025, driven by national need for immunization programs and expansion into different therapeutic areas.
After a grant from the Bill & Melinda Gates Foundation, Univercells will adapt its low-footprint, cabinet-contained vaccine production line to create affordable measles and rubella vaccinations.
As the US faces a measles outbreak, and bills removing rights to exempt from vaccination are debated, vaccine manufacturers stress the need to educate the public.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.
Fujifilm Diosynth has developed its ability to transition products from research to GMP, answering a big challenge as more parties look to get involved in the space, says COO.
